Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · page 33 of 50
The table contrasts established drugs (with confirmed exposure-response) against newer anti-TL1A agents (PRA023, RVT-3101) where this relationship is currently TBD.
Deck · key_takeaways · compare_peers · dense density
Slide locked Sign in to view
Slide schematic 5/5
callout 1/1 list 1/1 source-note 1/1 table 1/1 title 1/1
Components 5
primary bullet source-note data headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.